On Invalid Date, Lexaria Bioscience (NASDAQ: LEXX) reported Q1 2024 earnings per share (EPS) of -$0.06, up 72.73% year over year. Total Lexaria Bioscience earnings for the quarter were -$649.54 thousand. In the same quarter last year, Lexaria Bioscience's earnings per share (EPS) was -$0.22.
As of Q2 2024, Lexaria Bioscience's earnings has grown year over year. Lexaria Bioscience's earnings in the past year totalled -$5.45 million.
What was LEXX's revenue last quarter?
On Invalid Date, Lexaria Bioscience (NASDAQ: LEXX) reported Q1 2024 revenue of $145.00 thousand up 624.09% year over year. In the same quarter last year, Lexaria Bioscience's revenue was $20.03 thousand.
What was LEXX's revenue growth in the past year?
As of Q2 2024, Lexaria Bioscience's revenue has grown 17.46% year over year. This is 136.39 percentage points lower than the US Biotechnology industry revenue growth rate of 153.85%. Lexaria Bioscience's revenue in the past year totalled $386.00 thousand.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.